We are live on ! Find out more
BJCM

Blue Jay Capital Management Portfolio holdings

AUM $147M
1-Year Est. Return 64.18%
This Fund
S&P 500
This Quarter Est. Return
+11.67%
1 Year Est. Return
+64.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$147M
AUM Growth
-$56.7M
Cap. Flow
-$65.5M
Cap. Flow %
-44.61%
Top 10 Hldgs %
58.43%
Holding
30
New
9
Increased
3
Reduced
8
Closed
10

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$7.05M
2
QGEN icon
Qiagen
QGEN
+$6.94M
3
SNN icon
Smith & Nephew
SNN
+$6.77M
4
BKD icon
Brookdale Senior Living
BKD
+$6.22M
5
ICLR icon
Icon
ICLR
+$5.6M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$12.7M
2
GMED icon
Globus Medical
GMED
+$11.8M
3
QGENF
QIAGEN NV
QGENF
+$11.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$10.9M
5
BCR
CR Bard Inc.
BCR
+$9.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$9.44M 6.43%
67,490
-17,159
-20% -$2.48M
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
$9.28M 6.32%
99,101
-50,899
-34% -$3.11M
INCY icon
3
Incyte
INCY
$25.8B
$9.07M 6.18%
72,051
+2,373
+3% +$302K
IRWD icon
4
Ironwood Pharmaceuticals
IRWD
$702M
$8.87M 6.05%
561,180
-244,770
-30% -$3.56M
WMGI
5
DELISTED
Wright Medical Group Inc
WMGI
$8.81M 6%
320,420
+14,255
+5% +$403K
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12.8B
$8.58M 5.85%
94,454
-10,546
-10% -$959K
PRAH
7
DELISTED
PRA Health Sciences, Inc.
PRAH
$7.99M 5.45%
106,555
-33,445
-24% -$2.32M
EW icon
8
Edwards Lifesciences
EW
$51.7B
$7.95M 5.42%
201,798
-68,202
-25% -$2.49M
ABMD
9
DELISTED
Abiomed Inc
ABMD
$7.94M 5.41%
55,387
-19,613
-26% -$2.64M
NVRO
10
DELISTED
NEVRO CORP.
NVRO
$7.82M 5.33%
105,000
+5,000
+5% +$401K
QGEN icon
11
Qiagen
QGEN
$8.98B
$7.31M 4.98%
+205,543
New +$6.94M
SNN icon
12
Smith & Nephew
SNN
$12.1B
$6.97M 4.75%
+200,000
New +$6.77M
PTLA
13
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$6.74M 4.59%
+120,000
New +$4.81M
NBIX icon
14
Neurocrine Biosciences
NBIX
$15.9B
$6.68M 4.55%
+145,303
New +$7.05M
BKD icon
15
Brookdale Senior Living
BKD
$2.85B
$6.62M 4.51%
+450,000
New +$6.22M
ICLR icon
16
Icon
ICLR
$12.6B
$6.19M 4.22%
+63,342
New +$5.6M
VRTX icon
17
Vertex Pharmaceuticals
VRTX
$139B
$5.95M 4.06%
46,202
-33,959
-42% -$4.09M
ALGN icon
18
Align Technology
ALGN
$11.3B
$5.09M 3.47%
+33,904
New +$4.6M
ILMN icon
19
Illumina
ILMN
$32.8B
$4.77M 3.25%
+28,270
New +$4.89M
ISRG icon
20
Intuitive Surgical
ISRG
$129B
$4.68M 3.19%
+45,000
New +$4.32M
BIIB icon
21
Biogen
BIIB
$32.6B
– –
-46,320
Closed -$12.7M
BMY icon
22
Bristol-Myers Squibb
BMY
$137B
– –
-200,000
Closed -$10.9M
GMED icon
23
Globus Medical
GMED
$10.5B
– –
-400,000
Closed -$11.8M
MDRX
24
DELISTED
Veradigm Inc. Common Stock
MDRX
– –
-590,000
Closed -$7.48M
NUVA
25
DELISTED
NuVasive, Inc.
NUVA
– –
-123,317
Closed -$9.21M
1
2

Similar funds

BCM
Breithorn Capital Management New York $141M AUM 41.82% 1-Year Est. Return
RJA
Robshaw & Julian Associates Williamsville, New York $140M AUM 13.69% 1-Year Est. Return
RP
Ridgegate Proprietary Sydney, Australia $154M AUM 25.47% 1-Year Est. Return
ACPVT
ABS Capital Partners V Trust Baltimore, Maryland $123M AUM
SFA
Staton Financial Advisors Charlotte, North Carolina $118M AUM 11.07% 1-Year Est. Return
KL
Kinsight LLC Birmingham, Alabama $176M AUM 17.21% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $107M AUM 37.25% 1-Year Est. Return
KFS
Kissinger Financial Services Hunt Valley, Maryland $100M AUM 6.22% 1-Year Est. Return

Blue Jay Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Blue Jay Capital Management held 30 positions worth $147M, down 28% from $203M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Blue Jay Capital Management withdrew a net $65.5M in Q2 2017, closing 10 positions and reducing 8 holdings. Its most notable exit was Biogen, an estimated $12.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier.

Against the trend, Blue Jay Capital Management opened a new position in Neurocrine Biosciences worth $6.68M.

  • Blue Jay Capital Management's largest Q2 2017 buy was Neurocrine Biosciences: 145,303 shares worth $6.68M.
  • Blue Jay Capital Management added most to Wright Medical Group Inc in Q2 2017, an estimated $403K increase.
  • Blue Jay Capital Management's biggest Q2 2017 reduction was Vertex Pharmaceuticals, cutting an estimated $4.09M.
  • Blue Jay Capital Management fully exited Biogen in Q2 2017, selling an estimated $12.7M.
  • Blue Jay Capital Management's ten largest holdings make up 58% of its $147M portfolio in Q2 2017.
  • Blue Jay Capital Management opened 9 new positions and closed 10 in Q2 2017.
  • Blue Jay Capital Management's portfolio value fell 28% quarter-over-quarter to $147M.

Based on Blue Jay Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.